Expect formulation industry to surpass API industry: Peter Bains, CEO of Biocon Group

Biocon delves into the evolving dynamics of the biosimilar market, with a focus on its strategies and prospects for 2024-25 (FY25). PETER BAINSGroup CEO of Biocon, in a video interview with Aneeka Chatterjee, discusses their efforts to gain market share in key regions, the impact of lower prices for active pharmaceutical ingredients (APIs), and growth plans for biosimilars and generics. He also highlights Biocon’s strategic partnerships, debt reduction plans and expected recovery in their contract research activities. Edited excerpts:

Biosimilar earnings before interest, taxes, depreciation and amortization (Ebitda) margin returned to 24 percent despite high transition

First print: May 21, 2024 | 11:36 PM IST